Article

Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Department of Psychiatry and Behavioral Sciences, Winship Cancer Institute, Emory University School of Medicine, 1701 Uppergate Drive, WCI Building C, 5th Floor, Atlanta, GA 30322, USA.
Brain Behavior and Immunity (Impact Factor: 6.13). 10/2008; 23(2):149-58. DOI: 10.1016/j.bbi.2008.08.006
Source: PubMed

ABSTRACT Work in our laboratory has focused on the mechanisms by which cytokines can influence the brain and behavior in humans and non-human primates. Using administration of interferon (IFN)-alpha as a tool to unravel these mechanisms, we have expanded upon findings from the basic science literature implicating cytokine-induced changes in monoamine metabolism as a primary pathway to depression. More specifically, a role for serotonin metabolism has been supported by the clinical efficacy of serotonin reuptake inhibitors in blocking the development of IFN-alpha-induced depression, and the capacity of IFN-alpha to activate metabolic enzymes (indolamine 2,3 dioxygenase) and cytokine signaling pathways (p38 mitogen activated protein kinase) that can influence the synthesis and reuptake of serotonin. Our data also support a role for dopamine depletion as reflected by IFN-alpha-induced changes in behavior (psychomotor slowing and fatigue) and regional brain activity, which implicate the involvement of the basal ganglia, as well as the association of IFN-alpha-induced depressive-like behavior in rhesus monkeys with decreased cerebrospinal fluid concentrations of the dopamine metabolite, homovanillic acid. Neuroimaging data in IFN-alpha-treated patients also suggest that activation of neural circuits (dorsal anterior cingulate cortex) associated with anxiety and alarm may contribute to cytokine-induced behavioral changes. Taken together, these effects of cytokines on the brain and behavior appear to subserve competing evolutionary survival priorities that promote reduced activity to allow healing, and hypervigilance to protect against future attack. Depending on the relative balance between these behavioral accoutrements of an activated innate immune response, clinical presentations may be distinct and warrant individualized therapeutic approaches.

Full-text

Available from: Andrew H Miller, Dec 22, 2013
1 Follower
 · 
107 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: Inflammation is associated with symptoms in many chronic illnesses; however, this link has not been established in pulmonary arterial hypertension. Objectives: The objective of this study was to investigate the association between inflammatory markers and quality of life-related symptoms in patients with pulmonary arterial hypertension. We hypothesized that higher circulating interleukin-6 and tumor necrosis factor-alpha levels would be associated with worse quality of life-related symptoms. Methods: We performed a secondary analysis using baseline and 3 month assessments of 62 subjects in a clinical trial of aspirin and simvastatin to determine the association between plasma interleukin-6 and tumor necrosis factor-alpha levels and the Medical Outcomes Study Short Form-36 subscales (pain, vitality, mental health). Measurements and Main Results: The mean age was 49.7 + 13.4 years; 87% were female. Higher interleukin-6 levels were significantly associated with lower Medical Outcomes Study Short Form-36 subscale scores indicating worse bodily pain, vitality and mental health (all p < .01). Higher tumor necrosis factor-alpha levels were significantly associated with increased bodily pain, but better mental health scores. Conclusions: Interleukin-6 and tumor necrosis factor-alpha levels are associated with certain quality of life domains in patients with pulmonary arterial hypertension. Primary Sources of Funding: This study was partially funded by the National Institutes of Health grant K23 NR014885, R01 HL082895 and HL082895-S1, the American Nurses Foundation and the Biobehavioral Research Center at the University of Pennsylvania School of Nursing. Clinical trial registered with www.clinicaltrials.gov (NCT00384865) Word Count: 238.
    01/2015; 12(3). DOI:10.1513/AnnalsATS.201410-463OC
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Based on the urgent need for reliable biomarkers in relation to suicide risk both for more accurate prediction as well as for new therapeutic opportunities, several researchers have been studied evidences of the potential participation of inflammatory processes in the brain, in particular cytokines, in suicide. The purpose of this review was to analyze the associations between inflammation markers and suicide.Methods To achieve this goal, a systematic review of literature was conducted via electronic database Scopus using the Medical Subject Headings (MeSH) terms: “cytokines”, “suicide” and “inflammation”. Through this search it was found 54 articles. After analyzing them 15 met the eligibility criteria and were included in the final sample.ResultsOne of the most mentioned inflammatory markers was Interferon-α (IFN-α), a pro-inflammatory cytokine which has been shown to increase serum concentrations of pro-inflammatory cytokines such as interleukin (IL)-1, IL-6, tumor necrosis factor-a (TNF- α) and IFN-ϒ, which are factors increased suicide victims and attempters. In this line, IL-6 is not only found to be elevated in the cerebrospinal fluid of suicide attempters, even its levels in the peripheral blood have been proposed as a biological suicide marker. Another study stated that increased levels of IL-4 and IL-13 transcription in the orbitofrontal cortex of suicides suggest that these cytokines may affect neurobehavioral processes relevant to suicide.LimitationsA lack of studies and great amount of cross-sectional studies.Conclusion Inflammation may play an important role in the pathophysiology of suicide, especially, levels of some specific inflammatory cytokines.
    Journal of Affective Disorders 10/2014; 172. DOI:10.1016/j.jad.2014.09.057 · 3.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: El reconocimiento de que la inflamación podría representar un mecanismo habitual de las enfermedades se ha extendido hasta incluir los trastornos neuropsiquiátricos y, entre ellos, la depresión mayor. En pacientes con la enfermedad se observa un aumento de los biomarcadores inflamatorios en sangre periférica, incluidas las citocinas inflamatorias, que se ha demostrado que acceden al cerebro e interaccionan con prácticamente todas las esferas fisiopatológicas conocidas por participar en la depresión, incluido el metabolismo de los neurotransmisores, la función neuroendocrina y la plasticidad neural. De hecho, se cree que la activación de las vías inflamatorias dentro del cerebro contribuye a la confluencia de la disminución del soporte neurotrófico y la alteración de la liberación/recaptación de glutamato, al igual que el estrés oxidativo, lo que da lugar a una excitotoxicidad y la pérdida de los elementos gliales, lo que coincide con los hallazgos neuroanatomopatológicos que caracterizan los trastornos depresivos. Evidencian adicionalmente la relación entre inflamación y depresión los datos que demuestran que el estrés psicosocial, un precipitante bien conocido de los trastornos del humor, es capaz de estimular las moléculas de señalización inflamatoria, incluido el factor nuclear kappa B, en parte, a través de la activación de las vías eferentes del sistema nervioso simpático. Es interesante destacar el hallazgo de que los pacientes deprimidos con un aumento de los biomarcadores inflamatorios tienen más probabilidades de manifestar resistencia al tratamiento, y, en diversos estudios, el tratamiento antidepresivo se ha asociado con una disminución de las respuestas inflamatorias. Por último, los datos preliminares procedentes de pacientes con procesos inflamatorios, al igual que de pacientes deprimidos sin antecedentes patológicos, sugieren que la inhibición de las citocinas proinflamatorias o sus vías de señalización podría mejorar el humor depresivo y aumentar la respuesta al tratamiento con fármacos antidepresivos convencionales. Las implicaciones translacionales de estos hallazgos incluyen la oportunidad exclusiva de identificar las poblaciones pertinentes de pacientes, aplicar tratamientos inmunodirigidos y, además de la conducta, monitorizar la eficacia terapéutica a nivel del sistema inmunitario.
    04/2010; 17(2):71-80. DOI:10.1016/j.psiq.2010.04.001